June 30, 2015

Company: RIBOMIC Inc.
President & CEO: Yoshikazu Nakamura
(Code: 4591, Tokyo Stock Exchange Mothers)
Inquiries: Masayuki Miyazaki, Board Director (Business Administration)
Phone: +81-3-3440-3303

Announcement of the Contract Extension for Collaborative Research between RIBOMIC Inc. and Otsuka Pharmaceutical Co., Ltd.

We are pleased to announce that the collaborative research contract on project RBM001 with Otsuka Pharmaceutical Co., Ltd. (originally contracted on June 10, 2010 and being terminated on June 30, 2015) will be extended until December 31, 2015.

Project RBM001 focuses therapeutic aptamer against Midkine in inflammatory diseases.

There is no amendment to our financial estimate for the full fiscal year ending March 31, 2016.